Abstract 214P
Background
Epithelial-Mesenchymal Transition (EMT) is a dynamic process hypothesized to occur in carcinoma during invasion and metastasis. Tyrosine Kinase Inhibitor Sunitinib stands as the main first-line treatment in metastatic renal clear cell carcinoma (mRCC). Activation of IGF and TGFβpathways are known to be associated with the acquisition of EMT and chemoresistance in cancer cells. Downregulation of EMT regulators is a promising therapeutic strategy to overcome resistance or resensitize RCC to Sunitinib therapy. Furthermore, indirect and specific inhibition of IGF axis by inhibition of PAPP-A, which regulates IGF signaling, represents a novel approach in mRCC treatment.
Methods
RCC tumor tissues, primary and metastatic RCC cell lines (parental and Sunitinib resistant) were examined for EMT proteins (Ecad & Ncad), EMT regulators, TGFβ and IGF/PAPP-A axis by qRT-PCR and western blot. Analysis of TCGA transcriptome profiling dataset was performed.
Results
Higher expression of N cadherin and low expression of E cadherin indicating mesenchymal signature was noted in RCC patient tumors associated with significantly upregulated expression of known EMT inducers; TGFβ and IGF1R as compared to non-tumor adjacent kidney tissues. Expression of IGF1 axis components, EMT markers and TGFβ was confirmed via qRT-PCR in primary and metastatic RCC cell lines. Sunitinib-induced EMT was confirmed by upregulation of N cad and downregulation of Ecad in 786-O RCC cell line. Analysis of TCGA dataset revealed that IGF1R expression (n = 792, HR 1.45, p = 0.01) and TGFβ expression (n = 792, HR 2.14, p < 0.01) resulted in worse overall survival in mRCC patients, a non-significant trend towards worse survival was noted with PAPP-A expression (n = 792, HR 1.27, p = 0.1).
Conclusions
Our data suggest that EMT may play a role in RCC progression and may be a mechanism of drug resistance to Sunitinib. TGFβ and IGF pathways are dysregulated in RCC, therefore direct or indirect targeting of these pathways may prove to be a novel strategy to delay resistance to Sunitinib or resensitize RCC to VEGF inhibitor therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fiona Elsey Cancer Research Institute.
Funding
Fiona Elsey Cancer Research Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract